

Piers E M Patten

List of Publications by Citations

Source: <https://exaly.com/author-pdf/8770079/piers-e-m-patten-publications-by-citations.pdf>

Version: 2024-04-24

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

61
papers

1,515
citations

17
h-index

38
g-index

66
ext. papers

2,272
ext. citations

5.8
avg, IF

4.03
L-index

#	Paper	IF	Citations
61	Safety and immunogenicity of one versus two doses of the COVID-19 vaccine BNT162b2 for patients with cancer: interim analysis of a prospective observational study. <i>Lancet Oncology, The</i> , 2021 , 22, 765-778	21.7	240
60	CD38 expression in chronic lymphocytic leukemia is regulated by the tumor microenvironment. <i>Blood</i> , 2008 , 111, 5173-81	2.2	173
59	A novel adoptive transfer model of chronic lymphocytic leukemia suggests a key role for T lymphocytes in the disease. <i>Blood</i> , 2011 , 117, 5463-72	2.2	156
58	Outcomes of COVID-19 in patients with CLL: a multicenter international experience. <i>Blood</i> , 2020 , 136, 1134-1143	2.2	132
57	Ibrutinib Plus Venetoclax in Relapsed/Refractory Chronic Lymphocytic Leukemia: The CLARITY Study. <i>Journal of Clinical Oncology</i> , 2019 , 37, 2722-2729	2.2	120
56	Interaction with vascular endothelium enhances survival in primary chronic lymphocytic leukemia cells via NF-kappaB activation and de novo gene transcription. <i>Cancer Research</i> , 2010 , 70, 7523-33	10.1	75
55	Genome-edited, donor-derived allogeneic anti-CD19 chimeric antigen receptor T cells in paediatric and adult B-cell acute lymphoblastic leukaemia: results of two phase 1 studies. <i>Lancet, The</i> , 2020 , 396, 1885-1894	40	71
54	Poor outcome and prolonged persistence of SARS-CoV-2 RNA in COVID-19 patients with haematological malignancies; King's College Hospital experience. <i>British Journal of Haematology</i> , 2020 , 190, e279-e282	4.5	60
53	Evidence for a macromolecular complex in poor prognosis CLL that contains CD38, CD49d, CD44 and MMP-9. <i>British Journal of Haematology</i> , 2011 , 154, 216-22	4.5	60
52	Acute Immune Signatures and Their Legacies in Severe Acute Respiratory Syndrome Coronavirus-2 Infected Cancer Patients. <i>Cancer Cell</i> , 2021 , 39, 257-275.e6	24.3	50
51	IGHV-unmutated and IGHV-mutated chronic lymphocytic leukemia cells produce activation-induced deaminase protein with a full range of biologic functions. <i>Blood</i> , 2012 , 120, 4802-11	2.2	42
50	Efficacy of venetoclax monotherapy in patients with relapsed chronic lymphocytic leukaemia in the post-BCR inhibitor setting: a UK wide analysis. <i>British Journal of Haematology</i> , 2019 , 185, 656-669	4.5	32
49	Interim results of the safety and immune-efficacy of 1 versus 2 doses of COVID-19 vaccine BNT162b2 for cancer patients in the context of the UK vaccine priority guidelines		27
48	Chronic lymphocytic leukemia cells diversify and differentiate in vivo via a nonclassical Th1-dependent, Bcl-6-deficient process. <i>JCI Insight</i> , 2016 , 1,	9.9	22
47	Guideline for the treatment of chronic lymphocytic leukaemia: A British Society for Haematology Guideline. <i>British Journal of Haematology</i> , 2018 , 182, 344-359	4.5	20
46	Phenotype and immune function of lymph node and peripheral blood CLL cells are linked to transendothelial migration. <i>Blood</i> , 2016 , 128, 563-73	2.2	19
45	Ibrutinib Plus Venetoclax in Relapsed/Refractory CLL: Results of the Bloodwise TAP Clarity Study. <i>Blood</i> , 2018 , 132, 182-182	2.2	19

44	Real-World Data of High-Grade Lymphoma Patients Treated with CD19 CAR-T in England. <i>Blood</i> , 2019 , 134, 767-767	2.2	17
43	Triggering interferon signaling in T cells with avadomide sensitizes CLL to anti-PD-L1/PD-1 immunotherapy. <i>Blood</i> , 2021 , 137, 216-231	2.2	17
42	Effect of CD3/CD28 bead-activated and expanded T cells on leukemic B cells in chronic lymphocytic leukemia. <i>Journal of Immunology</i> , 2005 , 174, 6562-3; author reply 6563	5.3	12
41	Efficacy and Safety of Tisagenlecleucel in Adult Patients with Relapsed/Refractory Follicular Lymphoma: Interim Analysis of the Phase 2 Elara Trial. <i>Blood</i> , 2020 , 136, 1-3	2.2	12
40	COVID-19 in patients with CLL: improved survival outcomes and update on management strategies. <i>Blood</i> , 2021 , 138, 1768-1773	2.2	12
39	Torque teno virus 10 isolated by genome amplification techniques from a patient with concomitant chronic lymphocytic leukemia and polycythemia vera. <i>Molecular Medicine</i> , 2011 , 17, 1338-48	6.2	10
38	Tisagenlecleucel in adult relapsed or refractory follicular lymphoma: the phase 2 ELARA trial.. <i>Nature Medicine</i> , 2021 ,	50.5	10
37	Continued Long Term Responses to Ibrutinib + Venetoclax Treatment for Relapsed/Refractory CLL in the Blood Cancer UK TAP Clarity Trial. <i>Blood</i> , 2020 , 136, 17-18	2.2	10
36	Umbralisib monotherapy demonstrates efficacy and safety in patients with relapsed/refractory marginal zone lymphoma: A multicenter, open label, registration directed phase II study.. <i>Journal of Clinical Oncology</i> , 2019 , 37, 7506-7506	2.2	9
35	The architecture of neoplastic follicles in follicular lymphoma; analysis of the relationship between the tumor and follicular helper T cells. <i>Haematologica</i> , 2020 , 105, 1593-1603	6.6	9
34	Humoral and cellular immunity to delayed second dose of SARS-CoV-2 BNT162b2 mRNA vaccination in patients with cancer. <i>Cancer Cell</i> , 2021 , 39, 1445-1447	24.3	8
33	ALK-positive large B-cell lymphoma with strong CD30 expression; a diagnostic pitfall and resistance to brentuximab and crizotinib. <i>Histopathology</i> , 2016 , 69, 880-882	7.3	8
32	Ibrutinib Plus Rituximab Is Superior to FCR in Previously Untreated CLL: Results of the Phase III NCRI FLAIR Trial. <i>Blood</i> , 2021 , 138, 642-642	2.2	7
31	Outcome for patients with relapsed/refractory aggressive lymphoma treated with gemcitabine and oxaliplatin with or without rituximab; a retrospective, multicentre study. <i>Leukemia and Lymphoma</i> , 2017 , 58, 1-9	1.9	6
30	and evidence for uncoupling of B-cell receptor internalization and signaling in chronic lymphocytic leukemia. <i>Haematologica</i> , 2018 , 103, 497-505	6.6	6
29	Targeting the tumor microenvironment in chronic lymphocytic leukemia. <i>Haematologica</i> , 2021 , 106, 2317-2324	7.3	6
28	Risk of COVID-19 death in cancer patients: an analysis from Guy's Cancer Centre and King's College Hospital in London. <i>British Journal of Cancer</i> , 2021 , 125, 939-947	8.7	5
27	Engraftment of CLL-Derived T Cells in NSG Mice Is Feasible, Can Support CLL Cell Proliferation, and Eliminates the Need for Third Party Antigen Presenting Cells. <i>Blood</i> , 2011 , 118, 975-975	2.2	4

26	Management of cardiovascular complications of bruton tyrosine kinase inhibitors. <i>British Journal of Haematology</i> , 2021 ,	4.5	4
25	A retrospective analysis of post-transplant lymphoproliferative disorder following liver transplantation. <i>European Journal of Haematology</i> , 2018 , 100, 98-103	3.8	3
24	Worldwide Examination of Patients with CLL Hospitalized for COVID-19. <i>Blood</i> , 2020 , 136, 45-49	2.2	2
23	Eliciting Anti-Tumor T Cell Immunity in Chronic Lymphocytic Leukemia (CLL) with PD-L1/PD-1 Blockade Is Enhanced By Avadomide Immunotherapy through the Triggering of Immunogenic Interferon Signaling. <i>Blood</i> , 2018 , 132, 237-237	2.2	2
22	Sudden or Cardiac Deaths on Ibrutinib-Based Therapy Were Associated with a Prior History of Hypertension or Cardiac Disease and the Use of ACE-Inhibitors at Study Entry: Analysis from the Phase III NCRI FLAIR Trial. <i>Blood</i> , 2021 , 138, 2636-2636	2.2	2
21	Early FDG PET response predicts CAR-T failure in large B-cell lymphoma. <i>Blood Advances</i> , 2021 ,	7.8	2
20	Gene-edited healthy donor CAR T cells show superior anti-tumour activity compared to CAR T cells derived from patients with lymphoma in an in vivo model of high-grade lymphoma. <i>Leukemia</i> , 2021 , 35, 3581-3584	10.7	2
19	Human Herpesvirus 6 Encephalitis Following Treatment for Refractory Diffuse Large B Cell Lymphoma. <i>HemaSphere</i> , 2021 , 5, e535	0.3	2
18	Lymphoma diagnosis: an update. <i>Clinical Medicine</i> , 2007 , 7, 620-4	1.9	1
17	IL-6 Production by B-CLL Cells Plays a Critical Role in the Inhibition of T Cell Activation and Proliferation and Promotes a Th2 Response in Normal T Lymphocytes.. <i>Blood</i> , 2006 , 108, 2808-2808	2.2	1
16	Efficacy of Tisagenlecleucel in Adult Patients (Pts) with High-Risk Relapsed/Refractory Follicular Lymphoma (r/r FL): Subgroup Analysis of the Phase II Elara Study. <i>Blood</i> , 2021 , 138, 131-131	2.2	1
15	Richter transformation of chronic lymphocytic leukaemia: a British Society for Haematology Good Practice Paper. <i>British Journal of Haematology</i> , 2021 ,	4.5	1
14	Lenalidomide Promotes The Expansion Of CD8 T Cells With An Effector Memory Phenotype In a Murine Xenograft Model Of Chronic Lymphocytic Leukemia. <i>Blood</i> , 2013 , 122, 119-119	2.2	1
13	A Detailed Analysis of Parameters Supporting the Engraftment and Growth of Chronic Lymphocytic Leukemia Cells in Immune-Deficient Mice. <i>Frontiers in Immunology</i> , 2021 , 12, 627020	8.4	1
12	Colitis After CAR T-Cell Therapy for Refractory Large B-Cell Lymphoma Responds to Anti-Integrin Therapy. <i>Inflammatory Bowel Diseases</i> , 2021 , 27, e45-e46	4.5	1
11	Laser capture microscopy as a tool for the assessment of lineage-specific chimaerism from archived blood and bone marrow films. <i>British Journal of Haematology</i> , 2007 , 136, 677-8	4.5	0
10	Ibrutinib and Obinutuzumab in CLL: MRD Responses Sustained for Several Years with Deepest MRD Depletion in Patients with >1 Year Prior Ibrutinib Exposure. <i>Blood</i> , 2020 , 136, 27-28	2.2	0
9	B-cell chronic lymphocytic leukemia/lymphoma 2013 , 196-214		

- 8 Expansion of T Follicular Helper Cells in NLC Co-Cultures Reinforces the Concept of Co-Evolution of CLL and Supportive T Helper Cell Clones. *Blood*, **2021**, 138, 3716-3716 2.2
- 7 In-Situ Proliferation May Explain the Persistence of Host Derived Langerhans Cells Following Allogeneic Hematopoietic Stem Cell Transplantation with Reduced Intensity Conditioning.. *Blood*, **2007**, 110, 1196-1196 2.2
- 6 Detection of Activation-Induced Cytidine Deaminase RNA In CLL Cells Correlates with Shorter Patient Survival and High Numbers of CD38+ Cells. *Blood*, **2010**, 116, 2415-2415 2.2
- 5 Chronic Lymphocytic Leukemia B Cells Variably Express Functional Activation-Induced Cytosine Deaminase Protein. *Blood*, **2010**, 116, 378-378 2.2
- 4 Human CLL Intraclonal Fractions Differ in Their Abilities to Respond to, Elicit, and Suppress Pro-Engraftment and Growth Signals From Autologous T Cells in a Murine Adoptive Transfer Model. *Blood*, **2012**, 120, 316-316 2.2
- 3 Ultra-Deep Sequencing of De Novo IGHV Mutations in Activated CLL Cells: Evidence for Activation-Induced Deaminase Function.. *Blood*, **2012**, 120, 2545-2545 2.2
- 2 Evaluation of IGHV Ultra-Deep Sequences for Activation-Induced Deaminase Characteristics in CLL Cells after T Cell Stimulation. *Blood*, **2013**, 122, 2583-2583 2.2
- 1 Chronic lymphocytic leukaemia. *Medicine*, **2021**, 49, 286-292 0.6